Data on SVCT2 transporter expression and localization in cancer cell lines and tissues

Roa, Francisco J.; Peña, Emilio Duro; Inostroza, Eveling; Sotomayor, Kirsty; González, Mauricio; Gutierrez-Castro, Francisco A.; Maurin, Michelle; Sweet, Karen; Labrousse, Claire; Gatica, Marcell; Aylwin, Carlos F.; Mendoza, Pamela; Maldonado, Mauricio; Delgado, Carolina; Madariaga, Jaime; Panes, Jessica; Silva-Grecchi, Tiare; Concha, Ilona I.; Moraga-Cid, Gustavo; Reyes, Alejandro; Muñoz-Montesino, Carola; Vera, Juan Carlos; Rivas, Coralia I.

doi:10.1016/j.dib.2019.103972

Cited by 9 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the presence of SVCT2 in breast cancer may act as a predictor for the effectiveness of ascorbate treatment [ 115 ]. SCVT2 was overexpressed in the mitochondria of breast cancer cells, but only marginally presented on the plasma membrane [ 116 ]. Augmented expression of mitochondrial SVCT2 appears to be a common hallmark across all human cancers and might have implications for the survival capacity of cancer cells in pro-oxidant environments [ 116 , 191 ].…”

Section: Ascorbate Transportersmentioning

confidence: 99%

Relevant Membrane Transport Proteins as Possible Gatekeepers for Effective Pharmacological Ascorbate Treatment in Cancer

et al. 2023

View full text Add to dashboard Cite

Despite the increasing number of newly diagnosed malignancies worldwide, therapeutic options for some tumor diseases are unfortunately still limited. Interestingly, preclinical but also some clinical data suggest that the administration of pharmacological ascorbate seems to respond well, especially in some aggressively growing tumor entities. The membrane transport and channel proteins are highly relevant for the use of pharmacological ascorbate in cancer therapy and are involved in the transfer of active substances such as ascorbate, hydrogen peroxide, and iron that predominantly must enter malignant cells to induce antiproliferative effects and especially ferroptosis. In this review, the relevant conveying proteins from cellular surfaces are presented as an integral part of the efficacy of pharmacological ascorbate, considering the already known genetic and functional features in tumor tissues. Accordingly, candidates for diagnostic markers and therapeutic targets are mentioned.

show abstract

Section: Ascorbate Transportersmentioning

confidence: 99%

Relevant Membrane Transport Proteins as Possible Gatekeepers for Effective Pharmacological Ascorbate Treatment in Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Human breast cancer tissues expressed SVCT2, but were not able to take up AA. This was explained by the fact that this form of SVCT2 was absent from the plasma membrane and expressed in mitochondria of breast cancer cells (78). Augmented expression of the SVCT2 mitochondrial form and mitochondrial sequestration of AA might profoundly alter AA-dependent mechanisms in other subcellular compartments and might represent an adaptation mechanism to the special metabolic features in cancer cells.…”

Section: Vitamin C Compartmentalization: Unifying the Different Diseamentioning

confidence: 99%

Arterial Tortuosity Syndrome: An Ascorbate Compartmentalization Disorder?

Boel

Veszelyi

Németh

et al. 2021

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

Significance: Cardiovascular disorders are the most important cause of morbidity and mortality in the Western world. Monogenic developmental disorders of the heart and vessels are highly valuable to study the physiological and pathological processes in cardiovascular system homeostasis. The arterial tortuosity syndrome (ATS) is a rare, autosomal recessive connective tissue disorder showing lengthening, tortuosity, and stenosis of the large arteries, with a propensity for aneurysm formation. In histopathology, it associates with fragmentation and disorganization of elastic fibers in several tissues, including the arterial wall. ATS is caused by pathogenic variants in SLC2A10 encoding the facilitative glucose transporter (GLUT)10. Critical Issues: Although several hypotheses have been forwarded, the molecular mechanisms linking disrupted GLUT10 activity with arterial malformations are largely unknown. Recent Advances: The vascular and systemic manifestations and natural history of ATS patients have been largely delineated. GLUT10 was identified as an intracellular transporter of dehydroascorbic acid, which contributes to collagen and elastin cross-linking in the endoplasmic reticulum, redox homeostasis in the mitochondria, and global and gene-specific methylation/hydroxymethylation affecting epigenetic regulation in the nucleus. We revise here the current knowledge on ATS and the role of GLUT10 within the compartmentalization of ascorbate in physiological and diseased states. Future Directions: Centralization of clinical, treatment, and outcome data will enable better management for ATS patients. Establishment of representative animal disease models could facilitate the study of pathomechanisms underlying ATS. This might be relevant for other forms of vascular dysplasia, such as isolated aneurysm formation, hypertensive vasculopathy, and neovascularization. Antioxid. Redox Signal. 00, 000-000.

show abstract

“…A comprehensive study on this matter, focused on breast cancer cells mechanisms to acquire vitamin C was recently published (Pena et al, 2019;Roa et al, 2019). This work has shown that most (if not all) of the vitamin C that is capture by breast cancer cells is in the oxidized form.…”

Section: Vitamin C Transport and Compartmentalization In Cancer Cellsmentioning

confidence: 99%

Therapeutic Use of Vitamin C in Cancer: Physiological Considerations

et al. 2020

Self Cite

View full text Add to dashboard Cite

Since the early studies of William J. McCormick in the 1950s, vitamin C has been proposed as a candidate for the treatment of cancer. A number of reports have shown that pharmacological concentrations of vitamin C selectively kill cancer cells in vitro and decrease the growth rates of a number of human tumor xenografts in immunodeficient mice. However, up to the date there is still doubt regarding this possible therapeutic role of vitamin C in cancer, mainly because high dose administration in cancer patients has not showed a clear antitumor activity. These apparent controversial findings highlight the fact that we lack information on the interactions that occurs between cancer cells and vitamin C, and if these transformed cells can uptake, metabolize and compartmentalize vitamin C like normal human cells do. The role of SVCTs and GLUTs transporters, which uptake the reduced form and the oxidized form of vitamin C, respectively, has been recently highlighted in the context of cancer showing that the relationship between vitamin C and cancer might be more complex than previously thought. In this review, we analyze the state of art of the effect of vitamin C on cancer cells in vitro and in vivo, and relate it to the capacity of cancer cells in acquiring, metabolize and compartmentalize this nutrient, with its implications on the potential therapeutic role of vitamin C in cancer.

show abstract

Data on SVCT2 transporter expression and localization in cancer cell lines and tissues

Cited by 9 publications

References 3 publications

Relevant Membrane Transport Proteins as Possible Gatekeepers for Effective Pharmacological Ascorbate Treatment in Cancer

Relevant Membrane Transport Proteins as Possible Gatekeepers for Effective Pharmacological Ascorbate Treatment in Cancer

Arterial Tortuosity Syndrome: An Ascorbate Compartmentalization Disorder?

Therapeutic Use of Vitamin C in Cancer: Physiological Considerations

Contact Info

Product

Resources

About